Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them sooner.
Similar Posts
Decision: Parallel import licences granted in 2025
Parallel import licences granted in 2025.
Field Safety Notices: 4 to 8 August 2025
List of Field Safety Notices from 4 to 8 August 2025.
Guidance: Digital mental health technology: qualification and classification
Helping manufacturers define the characteristics of their devices and determine the appropriate regulatory qualification and classification.
MHRA calls on public to report side effects and suspected fakes during #MedSafetyWeek
The tenth annual #MedSafetyWeek brings together more than 130 medicines regulators and health organisations across 117 countries to encourage people to report suspected side effects from medicines and device incidents.
MHRA approves teplizumab to delay progression of type 1 diabetes
As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
MHRA approves adrenaline nasal spray – the first needle-free emergency treatment for anaphylaxis in the UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.